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Abstract
Background: Perifosine is a membrane-targeted alkylphospholipid developed to inhibit the PI3K/Akt pathway and
has been suggested as a favorable candidate for combined use with radiotherapy. In this study, we investigated
the effect of the combined treatment of perifosine and radiation (CTPR) on prostate cancer cells in vitro and on
prostate cancer xenografts in vivo.
Methods: Human prostate cancer cell line, CWR22RV1, was treated with perifosine, radiation, or CTPR. Clonogenic
survival assays, sulforhodamine B cytotoxity assays and cell density assays were used to assess the effectiveness of
each therapy in vitro. Measurements of apoptosis, cell cycle analysis by flow cytometry and Western blots were
used to evaluate mechanisms of action in vitro. Tumor growth delay assays were used to evaluate radiation
induced tumor responses in vivo.
Results: In vitro, CTPR had greater inhibitory effects on prostate cancer cell viability and clonogenic survival than
either perifosine or radiation treatment alone. A marked increase in prostate cancer cell apoptosis was noted in
CTPR. Phosphorylation of AKT-T308 AKT and S473 were decreased when using perifosine treatment or CTPR.
Cleaved caspase 3 was significantly increased in the CTPR group. In vivo, CTPR had greater inhibitory effects on the
growth of xenografts when compared with perifosine or radiation treatment alone groups.
Conclusions: Perifosine enhances prostate cancer radiosensitivity in vitro and in vivo. These data provide strong
support for further development of this combination therapy in clinical studies.
Background
Prostate cancer currently remains the most commonly
diagnosed malignancy and is second only to lung cancer
as the leading cause of tumor related death in males [1].
Radiotherapy (including external beam radiotherapy and
brachytherapy) remains a very important treatment
modality for prostate cancer. However, prostate cancer
cells can easily become radioresistant, resulting in poor
long term prognosis for many prostate cancer patients.
Therefore, it is now essential to clarify and target under-
lying mechanisms involved in the development of radio-
resistant cells to improve and optimize radiotherapy
strategies for prostate cancer patients.
Many molecular targets are differently expressed
between tumor and normal tissue types. This offers the
possibility of specific, biology-driven modulation radia-
tion responses in tumor and normal tissue types, and
thereby a therapeutic gain. In particular, the epidermal
growth factor receptor (EGFR) family has been targeted
to overcome radiation resistant cancer cell types [2].
The EGFR-activated phosphatidylinositide 3-kinase/Akt
(PI3K/Akt) pathway has been proposed to protect cells
from radiation-induced apoptosis by multiple mechan-
isms [3]. Deregulation of the PI3K/Akt pathway is often
associated with tumorigenesis [4,5] and poor prognosis
in cancer patients [6-8]. In addition, the PI3K/Akt path-
way has been implicated extensively as a contributor to
radioresistance [9]. These insights present the PI3K/Akt
pathway as an attractive target for anticancer therapy,
and more importantly, for combined treatment therapy.
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alkylphosphocholine analogue with antitumorigenic
activity and has been found to effectively inhibit Akt in
preclinical models. Other alkylphospholipids have
already been found to exhibit radiosensitizing properties
when used to treat squamous cell carcinoma [10-12]
malignant glioma [13], and lymphoma [14]. However,
the effect of alkylphospholipids on prostate cancer cells
has yet to be fully investigated. The results of a recent
Phase I/II clinical trial of perifosine failed to show sig-
nificant therapeutic response when used as a single
agent [15]. However, Vink et al. [16] suggest that alkyl-
phospholipids, including perifosine, are attractive candi-
dates for combination treatment with radiotherapy.
The aim of this study was to investigate the effect of
the combined treatment of perifosine and radiotherapy
on human prostate cancer.
Methods
Cell culture
The human prostate adenocarcinoma cell line,
CRW22RV1 [17] was cultured in RPMI 1640 containing
25 mM HEPES buffer, L-glutamine, 50 units/ml penicil-
lin, 50 μg/ml streptomycin and 10% fetal bovine serum
in a humidified incubator set to 37°C, 5% CO2.T h e
cells were plated and cultured to achieve 80-90% conflu-
ence on the day of experiments.
Radiation
For in vitro experiments, cells were irradiated at a dose
rate of 2.10 Gy per minute using the GAMMATOR B
Cs-137 irradiator (Radiation Machinery, Parsippany, NJ).
For in vivo experiments, mice were immobilized with
durative anesthesia by inhalation using the Table Top
Anesthesia Machine (VetEquip, Inc., Pleasanton, CA)
and a custom designed flake of plumbum, which allows
for specific radiation of a subcutaneous tumor while
shielding the rest of the animal. Xenografts were irra-
diated at a dose rate of ~1.56 Gy per minute using a
Phillips X-ray machine.
Perifosine treatment
Perifosine was purchased from Selleck Chemicals LLC.
For cell proliferation assays, cells were incubated from 24
to 144 hours with 10 μM perifosine. For measurements
of apoptosis, cells were incubated for 24 hours with 10
μM perifosine. For clonogenic survival assays, cells were
incubated for 48 hours with 15 μMo r3 0μM perifosine.
Cell proliferation assays
Cell viability was determined with a colorimetric 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium assay (MTS; Promega,
Madison, WI). Cells were seeded at a density of 5000
cells per well in 96-well plates. Immediately after perifo-
sine treatment, cells were treated with 6 Gy of radiation.
After treatment with perifosine for 24, 48, 72, 96, 120,
or 144 hours, 20 μL of MTS reagent was added to each
well. Two hours later, optical absorbance was measured
at 490 nm. Experiments were performed in triplicate
and repeated at least 3 times.
Clonogenic survival assays
Cells (200-10,000) were plated in 6-cm diameter dishes
and incubated 4 hours to allow the cells to attach. Cells
were then treated with perifosine and immediately
thereafter with 2 - 8 Gy of radiation. After 48 hours,
perifosine was removed and replaced with fresh med-
ium. Cells were allowed to form colonies over a period
of 14 days after treatment, which were subsequently
fixed and stained by 0.2% crystal violet. The number of
colonies containing at least 50 cells was determined
under a light microscope. The plating efficiency was cal-
culated by the number of colonies/cells seeded. The sur-
viving fraction at each dose was determined as a ratio of
plating efficiencies for irradiated and non-irradiated
cells, in which 100% corresponded to the non-irradiated
control for each group. The survival curves were plotted
by linear regression analyses. A D0 value, representing
the radiation dose that leads to 37% of cell survival, was
calculated. Sensitizing enhancement ratios (SER) were
then calculated based on the D0 values according to the
following formula.
SER = D0 untreated cells/D0 treated cells
Apoptosis measurement
Cells (1.2 × 10
5) were seeded in 6-cm diameter dishes
and incubated overnight to allow the cells to attach.
Cells were then treated with perifosine and immediately
thereafter with 6 Gy of radiation. Twenty-four hours
later, the media was replaced with fresh media. To avoid
losing apoptotic cells, supernatants were centrifuged and
cells in the media were collected and stored for further
study. An additional 24 hours later, cells and superna-
tants were collected, washed, and resuspended in
Nicoletti buffer. Apoptotic cells were measured by fluor-
escence activated cell sorting (FACS) after Annexin-
FITC and propidium iodide (PI) double staining using
the Annexin V Apoptosis Detection Kit, according to
the manufacturer’s protocol (BD, Franklin Lakes, NJ).
The percentages of apoptotic cells were analyzed using
FACScaliber software programs. Experiments were
repeated 3 times.
SDS-page and western blot analysis
Primary monoclonal antibodies against total AKT, phos-
phorylated AKT (Ser473 and Thr308) and cleaved caspase
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nologies (Beverly, MA). Antibodies against b-actin
were obtained from Chemicon (Temecula, CA). Horse-
radish peroxidase-conjugated secondary antibodies
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Total protein was extracted from cells
using cell lysis buffer (Cell Signaling Technology).
Cells were harvested in 4°C lysis buffer (150 mM
N a C l ,2 0m Mp H7 . 5T r i s - H C l ,1 %N P 4 0 ,1m M
EDTA) supplemented with protease cocktail (Roche,
Indianapolis, IN) and phosphatase I and II inhibitors
(Sigma, St. Louis, MO) on ice. Following centrifugation
at 14,000 rpm for 10 minutes at 4°C to remove the
insoluble fraction, protein concentrations of the super-
natants were determined by BCA assay (Pierce, Rock-
ford, IL). Cell lysates were mixed with Laemmli sample
buffer and placed in a boiling water bath for 5 min.
Equal amounts of protein (20 μg/lane) were loaded
into 10% sodium dodecyl sulfate-polyacrylamide gels
(Invitrogen, Carlsbad, CA) and separated by electro-
phoresis. Protein was then transferred electropho-
retically onto nitrocellulose membranes (Bio-Rad,
Hercules, CA). The membranes were blocked in 5%
skim milk in TBS-T (500 mM NaCl, 20 mM pH 7.5
Tris-HCl, 0.1% Tween 20) and incubated overnight at
4°C. The membranes were probed with primary anti-
bodies and secondary antibodies according to the man-
ufacturer’s instructions. The blots were analyzed by
chemiluminescence detection and autoradiography.
In vivo tumor growth delay assays
All animal studies were conducted in compliance with
VA Medical Center Animal Care and Use policy. Male
Athymic Nude-Foxn1nu mice, 6 to 7 weeks old (19.8-
26.5g), were purchased from Harlan Laboratories, Inc.
(Indianapolis, Indiana). Animals were kept and handled
under a 12h/12h light/dark cycle at 22°C, received a
standard diet and acidified water. Mice were given sub-
cutaneous injections of 5 × 10
6 cells in 100 μlH B S S
into the right hind limb and tumor size was measured
using calipers at least two times per week. Tumor
volume was calculated as π/6 × length × width × height,
where tumor volume at the start of treatment was nor-
malized to 100%. When tumors had grown to an aver-
a g ev o l u m eo f1 0 0m m
3, mice were separated into 4
groups: control (no perifosine, shame-irradiated, n =
10), perifosine (oral perifosine, n = 10), radiotherapy
(local tumor radiation, n = 9), and combined therapy
(oral administration of perifosine and local tumor radia-
tion, n = 11). Perifosine and combined groups were
given perifosine in a loading dose of 300 mg/kg (2 ×
1 5 0m g / k gs e p a r a t e db y1 2h o u r s )f o l l o w e db yd a i l y
maintenance doses of 35 mg/kg for 5 days. Two
fractions of 5 Gy radiation were delivered the next day
and 4 days after the start of perifosine treatment.
Results
Perifosine increases sensitivity of human CWR22RV1 cells
to radiation
In order to assess the effect of perifosine on prostate
cancer radiosensitivity, we first tested various doses of
perifosine exposure in combination with radiation treat-
ment in CWR22RV1 cells using the proliferation assay
(MTS assay) and the colony formation assay. We found
that the combination of perifosine and radiation had a
greater inhibitory effect on cell viability compared to
perifosine or radiation alone (Figure 1A). Similarly, the
combination of perifosine and radiation had a greater
inhibitory effect on colony formation compared to peri-
fosine or radiation alone (Figure 1B). The sensitization
enhancement ratios (SER) calculated based on the D0
value from 15 μMa n d3 0μM perifosine were 1.47 and
1.78, respectively. It is noted that for the survival curves
plotted, combinational survival was normalized by the
effect of perifosine alone on survival. The result of the
colony formation assay was confirmed in the prostate
cancer cell line PC-3 (Additional File 1, Figure S1).
Perifosine on radiation induced apoptosis and cell cycle
arrest
To assess the effect of perifosine on radiation-induced
apoptosis, we used Annexin-FITC based flow cytometry
analysis. Both nuclear fragmentation with propidium
iodine (PI) staining and translocated membrane phos-
phatidylserine (PS) with Annexin V staining were mea-
sured. Cells in early apoptosis shown in the right lower
quadrant were regarded as apoptotic cells (Figure 2A).
We found that both perifosine and radiation induced
significant apoptotic responses as shown by the increase
of apoptotic cell (Figure 2B). When radiation (6Gy) and
perifosine (10 μM) were combined, the number of apop-
totic cells was significantly increased (Figure 2B). This
apoptosis result was also confirmed in the prostate can-
cer cell line PC-3 (Additional File 1, Figure S2). We also
found that the level of cleaved caspase 3 was the highest
in the combined treatment group (Figure 2C), indicating
a potential mechanism of radiosensitization. We also
analyzed cell cycle checkpoints induced by perifosine,
radiation, or the combination using propidium iodine
(PI) staining followed by flow cytometry analysis. We
found that perifosine alone did not induce cell cycle
arrest at the G2/M phases and perifosine did not affect
the IR-induced G2/M checkpoint (data not shown).
These observations indicate that perifosine indu-
ced radiosensitization is independent of the G2/M
checkpoint.
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To determine the effect of the combination of perifosine
and radiation on Akt activity, we assessed expression
levels of phospho-Akt-Thr308 and phospho-Akt-Ser473
by Western blot. We found that while the radiation-only
group did not affect Akt-T308p and S473p, perifosine
significantly reduced phosphorylation of Akt (Figure 3).
More interestingly, combination of radiation with perifo-
sine further reduced Akt phosphorylation, suggesting a
synergistic inhibitory effect of perifosine and radiation
on AKT phosphorylation. Since phosphorylation of Akt
is linked to Akt activity, our results indicate that combi-
nation of perifosine with radiation can significantly
increase the inhibitory effect of perifosine on Akt.
Perifosine enhances prostate cancer radiosensitivity in
vivo
We then investigated the in vivo radiosensitization effect
of perifosine in a prostate cancer xenograft model in
nude mice. Perifosine treatment protocols in the clinical
setting typically involve an initial loading dose followed
by daily maintenance doses. Therefore, in an attempt to
simulate the clinically relevant treatment protocol, we
delivered perifosine as a loading dose followed by five
daily maintenance doses. Specifically, animals bearing
prostate cancer were given perifosine in an initial dose
of 300 mg/kg (2 × 150 mg/kg separated by 12 hours)
followed by daily maintenance doses of 35 mg/kg for 5
days. This perifosine treatment protocol was shown to
result in similar perifosine levels and pharmacokinetics
as in humans[16]. We found that perifosine alone did
not have a significant effect on tumor growth. However,
perifosine can significantly increase radiation induced
tumor growth delay (Figure 4A and Additional File 1Fig-
ure S3). To reach the 10-fold size of tumor volume to
the initial volume in the control, it took 15, 19, 41 and
59 days in control, perifosine only, radiation only and
combined treatment groups, respectively. It is noted that
in one case, the combined treatment led to a complete
remission of the CWR22RV1 tumor.
We also measured toxicity after irradiation and oral
perifosine treatment. The body weight of the nude mice
was monitored and used as an index for assessing the
systemic toxicity. In all experimental groups, no signifi-
cant weight loss due to local tumor irradiation was
observed. Body weight of control mice increased ~10%
within the first week, and then maintained this level for
two weeks. After the fourth week, mice lost ~5% body
weight due to dyscrasia. Perifosine alone resulted in a
slight but reversible weight loss (~5%), which was sus-
tained for 10 days. A reduction in body weight of ~6%
was observed in the combination group during the sec-
ond and third weeks. However, this weight loss was
reversible, as the body weight was regained within 3
weeks (Figure 4B). No lethal dose effect was observed.
Discussion
In this study, we showed enhancement of radiation-
induced cell death by the alkylphospholipid perifosine in
CWR22RV1 prostate cancer both in vitro and in vivo. In
vitro, perifosine reduced cell viability and clonogenic
survival, and enhanced apoptosis after radiation. In vivo,
substantial tumor growth delay was observed when peri-
fosine was combined with radiation.
As a single agent, perifosine has been reported to have
limited antitumor activity [18,19]. However, the combi-
nation of classical anticancer regimens with novel biolo-
gical response modifiers has potential to modulate
signal transduction pathways mediating apoptosis,
A
B
D
Control
IR
perifosine
Combined
Additiveeffect
Control
Perifosine15ʅM
Pefirosine30ʅM
Figure 1 Perifosine increases prostate cancer radiosensitivity in
vitro. A, CWR22RV1 cells were irradiated in the absence (control) or
the presence of 10 μM perifosine for 24 hours and the cell viability
was assessed using MTS assay. Shown are the means and standard
deviation of each individual treatment points. B, Cells were
irradiated in the absence (control) or in the presence of 15 μM and
30 μM perifosine and the colony formation assay was conducted.
Shown are the means and standard deviation of each individual
treatment points.
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rational candidate for combined modality approaches
[2,11,20]. Indeed, perifosine has demonstrated (supra-)
additive cytotoxicity in vitro when combined with other
drugs [21-24]. In addition, several alkylphospholipids
have been shown to enhance radiation-induced cell death
in a variety of tumor types in vitro [10,11,14,20,25]. The
following are possible mechanisms of Akt inhibition by
perifosine that have been suggested: 1) perifosine disrupts
the structure of and signaling within lipid rafts, prevent-
ing Akt recruitment to the membrane, 2) perifosine binds
directly to and inhibits the pleckstrin homology (PH)
domain of Akt [19]. In our study, reduced phospho-Akt-
T308 and phospho-Akt-S473 were observed in perifosine
alone and the combination groups, indicating radiation
combed with perifosine can increase the inhibitory effect
of perifosine on Akt, resulting in a synergistic effect.
Although Akt plays an important role in the mechan-
ism by which perifosine exerts its antitumor effect, Akt
is clearly not the only molecule involved. Other poten-
tial targets may include stimulation of the cellular
stress-related, apoptosis-inducing SAP/JNK pathway
[14,26]; stimulation of FAS clustering [27]; inhibition of
the MAP/ERK pathway [28]; inhibition of phospholipase
Control                IR           Perifosine         Combined
A
B C
ɴͲActin
Cleaved
CaspaseͲ3
Control IR Perifosine Combined
Control IR Perifosine Combined
Figure 2 Effects of perifosine on radiation-induced apoptosis and the G2/M checkpoint. A, CWR22RV1 cells were treated with perifosine
(10 μM), radiation (6Gy, IR), or combination as indicated. Cellular apoptosis was detected by FACs. B. Quantititative analysis of the FACs data.
C. CWR22RV1 cells were treated with control, radiation only (6Gy, IR), perifosine only (5 μM) or combination before they were subjected to the
Western blot analysis using indicated antibodies.
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Page 5 of 8C [29] and protein kinase C activation [30]; and stimula-
tion of ceramide formation [31]; and phospholipase D
[31,32]. At this time, further studies are needed to con-
firm other pathways involved in the antitumor effect of
combined perifosine and radiation treatment of prostate
cancer cells.
Hilgard et al. reported that a single oral (loading) dose
therapy with high-dose perifosine (68.1 mg/kg) caused
inhibition of tumor growth for about 14 days, and daily
oral treatments (for 25 days) at lower doses (2.5 to 46.4
mg/kg) also caused tumor growth inhibition. The onset
of response was found to be dose related. Responses
persisted for > 20 days after termination of therapy
without clear dose-response relationships over this
range [33]. Based on these results, a loading dose fol-
lowed by a lower daily maintenance dose schedule was
used in this study. Many Phase I/II studies have also
used a loading dose followed by maintenance dose sche-
dules, with reported loading doses ranging from 300
mg/kg to 1050mg/kg and maintenance doses ranging
from 50 mg/kg to 150 mg/kg [16]. Thus, we decided to
use 300 mg/kg for loading doses and 35mg/kg for daily
maintenance doses.
Vink et al. demonstrated complete and sustained
tumor regression of xenografted squamous cell carci-
noma after combined treatment of radiation and perifo-
sine [12]. Their schedule was based on daily doses
without loading doses. Although they demonstrated
complete tumor regression using a combination of 3 ×
40 mg/kg perifosine and 2 fractions of 5 Gy radiation
daily, our study could not achieve complete regression,
even when combining a 300 mg/kg perifosine loading
dose with 5 × 35 mg/kg perifosine and 2 fractions of 5
Gy radiation daily. Variation between our results and
previous results are likely caused by the differences in
radiosensitivity between squamous cell carcinoma and
prostate cancer cells, in addition to the differences
between schedules of drug administration. Further
studies should be performed to determine the best treat-
ment schedule for future clinical studies.
Conclusions
In conclusion, perifosine enhances prostate cancer
radiosensitivity, as evidenced by reduction of cell viabi-
lity, clonogenic survival, and the increase of apoptosis
in vitro and by tumor growth delay in vivo. These data
TotalAkt
pͲAktͲT308
pͲAktͲS473
Control IR Perifosine Combined
Figure 3 Perifosine and Akt activity. CWR22RV1 cells were treated
with control, radiation only (6Gy, IR), perifosine only (5 μM) or
combination before they were subjected to the Western blot
analysis using indicated antibodies.
A
B
Figure 4 Perifosine radiosensitizes prostate cancer in vivo.
A. Nude mice bearing CWR22RV1 xenografts with a mean volume
of 100 mm
3 were treated with control, perifosine alone, radiation
alone or combination. The tumor size was measured at least two
times a week and the tumor growth delay curve was displayed.
B, Changes of body weight after treatment.
Gao et al. Radiation Oncology 2011, 6:39
http://www.ro-journal.com/content/6/1/39
Page 6 of 8provide strong support for further development of this
combination therapy in clinical studies.
Additional material
Additional file 1: Figure S1: Radiosensitization of perifosine in
prostate cancer PC-3 cells. Cells were irradiated in the absence
(control) or in the presence of perifosine and the colony formation assay
was conducted. Shown are the means and standard deviation of each
individual treatment points. Figure S2: Perifosine and radiation induced
apoptosis in PC-3 cells. Cells were treated with perifosine (5 μM),
radiation, or combination as indicated. Cellular apoptosis was detected
by FACs. Shown are the mean values of the quantitative data. Figure S3:
Perifosine increases radiation induced tumor growth delay in vivo.
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